Amplifica Raised $26 Million to Continue Trials Research/Science 8/13/2026
Amplifica raised $26 million to advance its injectable treatments for hair growth. The funding will support the clinical development of their novel therapies.
View this post in the Community →
Similar Community Posts Join
5 / 5 resultscommunity Expectations control for SCUBE3
SCUBE3, a protein linked to hair growth in moles, was discovered over 25 years ago and is being developed by Amplifica for potential hair loss treatment. Concerns exist about SCUBE3's association with cancer, as it is a protein that promotes cell growth, which could potentially trigger cancer development if used for hair growth therapy.
community Most promising cures for baldness as of May 2026
PP405 is the most promising future treatment for hair loss, aiming to reactivate dormant hair follicles. Clascoterone 5% is the most promising near-term drug, while current strategies include using finasteride or dutasteride to stabilize hair loss and minoxidil to stimulate growth.
community Which 2026 hair‑loss treatments have the strongest evidence so far? (minoxidil/finasteride vs. clascoterone, PP405, Re:You’s NV‑623/624, AMP‑303, RU58841)
Minoxidil and finasteride are the only FDA-approved treatments for androgenetic alopecia, while newer treatments like clascoterone, PP405, NV-623/624, AMP-303, and RU58841 are still experimental with varying levels of evidence. Clascoterone shows the most promise due to strong human data, while AMP-303 has notable early human trial results; RU58841 lacks human data and remains experimental.
community Amplifica Sees Positive Results for Hair Loss Treatment - Results Show 15% increase in 60 days!
Amplifica's new injectable treatment for androgenetic alopecia shows a 15% increase in hair thickness and coarseness in 60 days. The treatment is in early human trials and offers a promising alternative to hormone-related hair loss treatments.
community Amplifica’s AMP-303 Study Unveils New Hope for Hair Loss Treatments
AMP-303, a new injectable treatment for androgenetic alopecia, showed promising results in increasing hair count and density with minimal side effects. The treatment demonstrated significant hair regrowth and durability, offering new hope for those with hair loss.
Related Research
6 / 6 resultsresearch Androgenetic alopecia: combing the hair follicle signaling pathways for new therapeutic targets and more effective treatment options
This review discusses emerging targets for developing drugs to treat hair loss and reports no new clinical results; the authors emphasize the potential for therapies that regenerate hair follicles.
research Mechanisms and clinical progress of adipose-derived stem cells and their derivatives in the treatment of hair loss
This review examines adipose-derived stem cells as a promising therapy for alopecia but reports no new clinical results, discussing their potential mechanisms and the challenges faced in treatment development.
research Fibroblast Growth Factor-7 and Hair Biology: Bridging Basic Science and Therapeutic Applications
This paper reviews the emerging role of FGF-7 signaling in hair regeneration, highlighting its potential as a target for new therapies despite limited clinical trial data.
research Extracellular Vesicles in Skin: Biological Function and Therapeutic Potential
This review discusses the roles of extracellular vesicles in skin health and disease and reports no clinical results; the authors highlight potential therapeutic uses and call for more research.
research Pharmacologic Modulation of Sebaceous Gland Activity: Mechanisms and Clinical Applications
This review discusses the mechanisms by which isotretinoin and hormonal therapy treat acne through their effects on sebaceous glands, reporting no new clinical results.
research Merkel cell carcinoma: updates in tumor biology, emerging therapies, and preclinical models
This review discusses recent advances in understanding Merkel cell carcinoma biology, including the development of genetically-engineered mouse models and potential therapeutic targets, but reports no new clinical results.